Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.
Sowalsky AG, Figueiredo I, Lis RT, Coleman I, Gurel B, Bogdan D, Yuan W, Russo JW, Bright JR, Whitlock NC, Trostel SY, Ku AT, Patel RA, True LD, Welti J, Jimenez-Vacas JM, Rodrigues DN, Riisnaes R, Neeb A, Sprenger CT, Swain A, Wilkinson S, Karzai F, Dahut WL, Balk SP, Corey E, Nelson PS, Haffner MC, Plymate SR, de Bono JS, Sharp A. Sowalsky AG, et al. Among authors: gurel b. Clin Cancer Res. 2022 Aug 15;28(16):3509-3525. doi: 10.1158/1078-0432.CCR-22-0851. Clin Cancer Res. 2022. PMID: 35695870 Free PMC article.
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity.
Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM, Nelson WG. Yegnasubramanian S, et al. Among authors: gurel b. Cancer Res. 2008 Nov 1;68(21):8954-67. doi: 10.1158/0008-5472.CAN-07-6088. Cancer Res. 2008. PMID: 18974140 Free PMC article.
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
Zafeiriou Z, Bianchini D, Chandler R, Rescigno P, Yuan W, Carreira S, Barrero M, Petremolo A, Miranda S, Riisnaes R, Rodrigues DN, Gurel B, Sumanasuriya S, Paschalis A, Sharp A, Mateo J, Tunariu N, Chinnaiyan AM, Pritchard CC, Kelly K, de Bono JS. Zafeiriou Z, et al. Among authors: gurel b. Eur Urol. 2019 Jan;75(1):184-192. doi: 10.1016/j.eururo.2018.09.048. Epub 2018 Oct 16. Eur Urol. 2019. PMID: 30340782 Free PMC article.
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G, Yuan W, Dolling D, Welti JC, Neeb A, Sumanasuriya S, Rescigno P, Bianchini D, Tunariu N, Carreira S, Sharp A, Oyen W, de Bono JS. Paschalis A, et al. Among authors: gurel b. Eur Urol. 2019 Oct;76(4):469-478. doi: 10.1016/j.eururo.2019.06.030. Epub 2019 Jul 22. Eur Urol. 2019. PMID: 31345636 Free PMC article.
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, Syndikus I, Ralph C, Jain S, Varughese M, Parikh O, Crabb S, Robinson A, McLaren D, Birtle A, Tanguay J, Miranda S, Figueiredo I, Seed G, Bertan C, Flohr P, Ebbs B, Rescigno P, Fowler G, Ferreira A, Riisnaes R, Pereira R, Curcean A, Chandler R, Clarke M, Gurel B, Crespo M, Nava Rodrigues D, Sandhu S, Espinasse A, Chatfield P, Tunariu N, Yuan W, Hall E, Carreira S, de Bono JS. Mateo J, et al. Among authors: gurel b. Lancet Oncol. 2020 Jan;21(1):162-174. doi: 10.1016/S1470-2045(19)30684-9. Epub 2019 Dec 2. Lancet Oncol. 2020. PMID: 31806540 Free PMC article. Clinical Trial.
Genomics of lethal prostate cancer at diagnosis and castration resistance.
Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I, Miranda S, Nava Rodrigues D, Gurel B, Clarke M, Atkin M, Chandler R, Messina C, Sumanasuriya S, Bianchini D, Barrero M, Petermolo A, Zafeiriou Z, Fontes M, Perez-Lopez R, Tunariu N, Fulton B, Jones R, McGovern U, Ralph C, Varughese M, Parikh O, Jain S, Elliott T, Sandhu S, Porta N, Hall E, Yuan W, Carreira S, de Bono JS. Mateo J, et al. Among authors: gurel b. J Clin Invest. 2020 Apr 1;130(4):1743-1751. doi: 10.1172/JCI132031. J Clin Invest. 2020. PMID: 31874108 Free PMC article. Clinical Trial.
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.
Minchom A, Yuan W, Crespo M, Gurel B, Figueiredo I, Wotherspoon A, Miranda S, Riisnaes R, Ferreira A, Bertan C, Pereira R, Clarke M, Baker C, Ang JE, Fotiadis N, Tunariu N, Carreira S, Popat S, O'Brien M, Banerji U, de Bono J, Lopez J. Minchom A, et al. Among authors: gurel b. J Immunother Cancer. 2020 Mar;8(1):e000713. doi: 10.1136/jitc-2020-000713. J Immunother Cancer. 2020. PMID: 32169873 Free PMC article.
Prostate carcinogenesis: inflammatory storms.
de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, Gil J, Drake CG, Alimonti A. de Bono JS, et al. Among authors: gurel b. Nat Rev Cancer. 2020 Aug;20(8):455-469. doi: 10.1038/s41568-020-0267-9. Epub 2020 Jun 16. Nat Rev Cancer. 2020. PMID: 32546840 Review.
99 results